Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686959 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT00686959 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 598 participants.
The verdict
NCT00686959, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Etoposide
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686959
The ClinicalTrials.gov registry entry for NCT00686959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00686959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686959 about?
NCT00686959 is a clinical study titled "Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer". This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
What is the current status of trial NCT00686959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2008-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00686959?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Etoposide (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00686959?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.